Equities Analysts Set Expectations for ENTA FY2026 Earnings

Key Points

• HC Wainwright lowered its FY2026 EPS estimate for Enanta Pharmaceuticals to a loss of $2.49 per share from a prior estimate of $2.18, while maintaining a “Buy” rating and $20 price target.
• Enanta’s latest quarterly results missed expectations: the company reported a $0.67-per-share loss versus the projected $0.51 loss, while revenue of $14.36 million fell short of the $16.76 million consensus estimate.
• Analyst sentiment remains cautiously positive, with six Buy ratings and one Sell rating producing a “Moderate Buy” consensus and an average price target of $19.50; institutional investors own nearly 95% of the stock.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Equities research analysts at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for shares of Enanta Pharmaceuticals in a report issued on Tuesday, August 11th. HC Wainwright analyst B. Folkes now forecasts that the biotechnology company will post earnings per share of ($2.49) for the year, down from their prior forecast of ($2.18). HC Wainwright currently has a "Buy" rating and a $20.00 target price on the stock. The consensus estimate for Enanta Pharmaceuticals' current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals' Q4 2026 earnings at ($0.95) EPS, FY2027 earnings at ($2.66) EPS, FY2028 earnings at ($3.37) EPS, FY2029 earnings at ($2.55) EPS and FY2030 earnings at ($2.17) EPS.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.16). The firm had revenue of $14.36 million for the quarter, compared to the consensus estimate of $16.76 million. Enanta Pharmaceuticals had a negative net margin of 96.89% and a negative return on equity of 61.61%.

A number of other brokerages have also recently commented on ENTA. Wall Street Zen cut shares of Enanta Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Sunday, May 31st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Enanta Pharmaceuticals in a research note on Friday, July 17th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $19.50.

Enanta Pharmaceuticals Trading Down 0.1%

ENTA opened at $13.50 on Thursday. The company has a market cap of $392.58 million, a price-to-earnings ratio of -5.60 and a beta of 0.98. The stock has a fifty day simple moving average of $13.18 and a two-hundred day simple moving average of $13.44. Enanta Pharmaceuticals has a 12-month low of $6.60 and a 12-month high of $17.15.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. bought a new stake in Enanta Pharmaceuticals in the fourth quarter worth $32,000. Seven Fleet Capital Management LP bought a new position in shares of Enanta Pharmaceuticals during the fourth quarter valued at $36,000. Strs Ohio purchased a new position in shares of Enanta Pharmaceuticals in the 4th quarter worth about $50,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Enanta Pharmaceuticals by 333.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,584 shares of the biotechnology company's stock worth $57,000 after purchasing an additional 2,758 shares during the last quarter. Finally, Clearstead Trust LLC bought a new position in Enanta Pharmaceuticals in the 2nd quarter worth about $74,000. Hedge funds and other institutional investors own 94.99% of the company's stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE's direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source